Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial.

Authors:

I. Adams-Chapman; K.L. Watterberg; T.L. Nolen; S. Hirsch; C.A. Cole; M. Cotten; W. Oh; B.B. Poindexter; K.M. Zaterka-Baxter; A. Das; C.Backstrom Lacy; A.Marie Scorsone; A.F. Duncan; S.B. DeMauro; R.F. Goldstein; T.T. Colaizy; D.E. Wilson-Costello; I.B. Purdy; S.R. Hintz; R.J. Heyne; G.J. Myers; J. Fuller; S. Merhar; H.M. Harmon; M. Peralta-Carcelen; H.W. Kilbride; N.L. Maitre; B.R. Vohr; G. Natarajan; H. Mintz-Hittner; G.E. Quinn; D.K. Wallace; R.J. Olson; F.H. Orge; I. Tsui; M. Gaynon; A.K. Hutchinson; Y.G. He; T.W. Winter; M.B. Yang; K.M. Haider; M.S. Cogen; D. Hug; D.L. Bremer; J.P. Donahue; W.R. Lucas; D.L. Phelps; R.D. Higgins; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network

Abstract:

OBJECTIVE: This study evaluates the 24-month follow-up for the NICHD Neonatal Research Network (NRN) Inositol for Retinopathy Trial.

STUDY DESIGN: Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial. Moderate/severe NDI was defined as BSID-III Cognitive or Motor composite score

Citation:

Adams-Chapman I, Watterberg KL, Nolen TL, et al. "Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial." J Perinatol. 2021;41(8):2072-2087.PubMed

Publication type:

Journal Article

Year:

2021

CPQCC publication:

Yes

PubMed ID:

33758387

PMCID:

PMC8349854